Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • Economics Weekly: Making Friends With the Taylor Rule

    In this Economics Weekly, we discuss why the Fed may have been right to keep rates below the Taylor rule’s policy prescription for the last two decades, and why a structural change in the inflation regime means it may no longer have that luxury.

    Read more

  • Climb Bio, Inc.: Initiation of Research Coverage

    William Blair initiated research coverage of Climb Bio, Inc. (CLYM $1.88), which is developing high-impact medicines for patients living with autoimmune diseases, with the CD19 antibody budoprutug as its lead program.

    Read more

  • The Pet Supplements Industry Is Booming and Requires More Capacity and Capabilities

    The pet supplements industry is on track for strong continued growth. Meeting future demand will require both additional capacity and enhanced capabilities to stay ahead of intensifying competition—creating opportunities for investors.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures